Findings seen compared with stereotactic body radiotherapy for early-stage disease<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, May 22, 2023 (HealthDay News) — Long-term survival favors surgical management over stereotactic body radiotherapy (SBRT) for treatment of early-stage, non-small cell lung cancer (NSCLC), according to a study presented at the annual meeting of the American Association for Thoracic Surgery, held from May 6 to 9 in Los Angeles.<\/p>\n
Brooks Udelsman, M.D., from Yale-New Haven Hospital in Connecticut, and colleagues evaluated trends in the utilization of SBRT and the long-term survival for SBRT versus surgery in otherwise healthy patients with early-stage NSCLC. The analysis included 24,729 patients (80.7 percent) who underwent surgery and 5,929 (19.3 percent) treated with SBRT.<\/p>\n
The researchers found that between 2012 and 2018, the proportion of patients receiving SBRT increased from 15.9 to 26.0 percent. Increasing age (odds ratio [OR], 1.09) and squamous histology (OR, 1.25) were associated with receiving SBRT. Among patients undergoing surgical resection, the 30-day and 90-day mortality rates were higher versus SBRT (1.7 versus 0.3 percent and 2.8 versus 1.7 percent, respectively). However, among surgically managed patients, the unadjusted five-year survival rate was higher (75.8 versus 40.5 percent). Using data from propensity-matched patients, survival favored SBRT for the first several months but separated after one year and significantly favored surgical management by year 2.<\/p>\n
“Among patients that are eligible for either treatment, the long-term survival appears to favor surgical management over SBRT, particularly for patients with a health-related life expectancy [exceeding] two years,” the authors write.<\/p>\n
Press Release<\/a><\/p>\n